Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hepatitis D virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    250 result(s) found for: Hepatitis D virus. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-000828-14 Sponsor Protocol Number: VX05-950-104EU Start Date*: 2006-06-13
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects with Hepatitis C
    Medical condition: Hepatitis C virus (HCV) infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019744 Hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002139-94 Sponsor Protocol Number: IPH1101-203 Start Date*: 2007-06-19
    Sponsor Name:Innate Pharma
    Full Title: Multiple dose Phase II study of IPH1101 in monotherapy or associated with a low dose of IL2 (2MIU) in non previously treated hepatitis C patients
    Medical condition: Non previously treated Hepatitis C patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002695-17 Sponsor Protocol Number: DEB-025-HCV-203 Start Date*: 2006-09-21
    Sponsor Name:DEBIOPHARM S.A.
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week i...
    Medical condition: treatment na ve patients with chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019744 Hepatitis C LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004154-28 Sponsor Protocol Number: GS-US-334-0124 Start Date*: 2013-02-15
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-i...
    Medical condition: Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022092-65 Sponsor Protocol Number: ACH625-003 Start Date*: 2011-10-13
    Sponsor Name:Achillion Pharmaceuticals, Inc.
    Full Title: A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in comb...
    Medical condition: Hepatitis C Virus Genotype 1
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10019751 Hepatitis C virus LLT
    14.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001071-40 Sponsor Protocol Number: ISM10-06 Start Date*: 2011-08-11
    Sponsor Name:InSpira Medical AB
    Full Title: A Phase IIa Safety study of oral administration of anti-CD3 monoclonal antibody in non-responder genotype-I chronic Hepatitis C subjects, a single-blind, randomized, controlled multi-center study
    Medical condition: in non-responder genotype-I chronic Hepatitis C subjects
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10047457 Viral hepatitis C LLT
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004905-29 Sponsor Protocol Number: TMC435HPC3014 Start Date*: 2013-08-19
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chro...
    Medical condition: Hepatitis C Virus (HCV) genotype-1 infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) AT (Completed) IT (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005500-14 Sponsor Protocol Number: MZ-ATRACTION/ML 20804 Start Date*: 2007-09-05
    Sponsor Name:Universitätsmedizin der Johannes-Gutenberg Universität Mainz
    Full Title: A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGA...
    Medical condition: chronic HCV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019183 HCV LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021716-42 Sponsor Protocol Number: 1220.30 Start Date*: 2011-03-11
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ...
    Medical condition: genotype 1 chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003737-40 Sponsor Protocol Number: 958 Start Date*: 2006-05-03
    Sponsor Name:Biotest AG
    Full Title: An open, prospective, randomised parallel study investigating efficacy and safety of the human hepatitis B immunoglobulin BT088 after subcutaneous or intramuscular application in liver transplanted...
    Medical condition: long-term prophylaxis against hepatitis B re-infection ≥ 3 months after liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    8.0 10019731 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004564-30 Sponsor Protocol Number: VX11-950-118 Start Date*: 2013-02-12
    Sponsor Name:Vertex Pharmaceuticals
    Full Title: A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17...
    Medical condition: genotype 1 Hepatitis C Virus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-004665-33 Sponsor Protocol Number: VX06-950-106 Start Date*: 2007-04-04
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral R...
    Medical condition: Hepatitis C virus (HCV) infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004043-23 Sponsor Protocol Number: IDX-04B-001 Start Date*: 2013-11-13
    Sponsor Name:Idenix Pharmaceuticals Inc.
    Full Title: A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects
    Medical condition: Hepatitis C virus
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021715-17 Sponsor Protocol Number: 1220.7 Start Date*: 2011-07-12
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot...
    Medical condition: Chronic hepatitis C infection genotype 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) BE (Completed) DE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000141-20 Sponsor Protocol Number: 1220.48 Start Date*: 2011-07-12
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C inf...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) DE (Completed) AT (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-004556-71 Sponsor Protocol Number: P05514 Start Date*: 2009-05-25
    Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation
    Full Title: Estudio de un solo grupo para facilitar tratamiento con boceprevir a sujetos con el genotipo 1 del virus de la hepatitis C crónica que no han respondido a peginterferón/ribavirina en estudios previ...
    Medical condition: Hepatitis C Crónica
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10019744 PT
    9.1 10021881 SOC
    9.1 10019805 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001213-17 Sponsor Protocol Number: MYR301 Start Date*: 2019-08-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients with Chronic Hepatitis Delta
    Medical condition: Chronic Hepatitis Delta
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10019763 Hepatitis delta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001485-15 Sponsor Protocol Number: MYR204 Start Date*: 2019-09-24
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta
    Medical condition: Chronic Hepatitis Delta
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10019763 Hepatitis delta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-005939-10 Sponsor Protocol Number: V232-055 Start Date*: 2006-05-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A study in healthy, young adults and healthy infants of the safety, tolerability, and immunogenicity of an investigational manufacturing process for the recombinant hepatitis B vaccine
    Medical condition: Hepatitis B ICD10 classification code : Hepatitis Viral- Type B (ICD10- B16) MedDRA classification code : Infections and Infestations – Viral Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    7.1 10019731 LLT
    Population Age: Infants and toddlers, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-001081-42 Sponsor Protocol Number: HepNet-aHCV-IV Start Date*: 2014-10-21
    Sponsor Name:Hannover Medical School
    Full Title: Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study
    Medical condition: Adults with acute genotype 1 hepatitis C virus (HCV) infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    18.1 10021881 - Infections and infestations 10065051 Acute hepatitis C PT
    18.1 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 13:01:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA